On the contrary, inhibition of PD-1 not only boosted the activation of cetuximab-induced NK cells, making them more potent against tumor cells expressing PD-Ligand 1 (PD-L1), but in patients with advanced CRC, cetuximab treatment also amplified intratumoral cytotoxic T lymphocytes (CTLs) and the presence of inhibitory immune checkpoint molecules such as those blocking the PD-1/PD-L1 pathway [88,89]. This evidence concerns the gene CD274 and colorectal carcinoma.